Goldman Sachs raised the firm’s price target on Arrowhead (ARWR) to $48 from $27 but keeps a Neutral rating on the shares. The firm is citing the announced FDA approval of Redemplo, formerly plozasiran, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome, in what it calls a “best case” label scenario, the analyst tells investors in a research note. Goldman adds however that Redemplo’s pricing could serve Arrowhead favorably in the near-term during the FCS launch, as both Ionis (IONS) and Arrowhead transition to the sHTG launch, the dynamic may become more nuanced.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead price target raised to $52 from $45 at RBC Capital
- Arrowhead price target raised to $70 from $45 at Piper Sandler
- Arrowhead Pharmaceuticals: Strong Market Position and Growth Potential with REDEMPLO’s FDA Approval
- Arrowhead Pharmaceuticals: Hold Rating Amid Market Challenges and Future Opportunities
- Arrowhead Pharmaceuticals’ REDEMPLO Approved by FDA